Brown University malaria research
The Kurtis and Bailey laboratories at Brown University develop new malaria medicines and vaccines and create genomic tools for tracking drug- and diagnostic-resistant parasites.
What they do
The Kurtis and Bailey laboratories at Brown University develop new malaria medicines and vaccines and create genomic tools for tracking drug- and diagnostic-resistant parasites.1,2 Their U.S. R&D is based in Providence, Rhode Island.2 Their work spans the discovery and development stages, including PfGARP and PfSEA-1 targets, preclinical vaccine and antibody candidates, novel small-molecule antimalarials, and genomics work focused on high-throughput sequencing drug-resistance pipelines for discovery and surveillance.2
In the field and in development
They have recently detected novel drug resistance locus PX1 in sub-Saharan Africa in addition to tracking the spread of artemisinin partial resistance due to Kelch13 mutations.
Partnerships in 6 endemic countries
- INRB · Country-wide genomic mapping of parasite transmission dynamics, cross-border gene flow, and drug-resistance spread (funded by NIH and BMGF)2
- Ethiopian Public Health Institute (EPHI) · National-scale tracking of dual-resistant parasites (diagnostic-escaping pfhrp2/3 deletions + artemisinin resistance)2
- Kenya Medical Research Institute (KEMRI) · Active field studies of severe malaria pathogenesis, target discovery, ex vivo drug discovery, and surveillance for drug-resistance mutations2
- INES-Ruhengeri (Rwanda) · Establishing genomic biology center and conducting target mutation tracking country-wide2
Who they work with in the United States
Where this comes from
- 1medical.brown.edu
- 2Confirmed by the organization
- 3brown.edu
- 4nature.com
- 5brown.edu
- 6patentsgazette.uspto.gov